Why does rasagiline cost so much compared with other Parkinson’s drugs?
Rasagiline is priced high largely because it is a branded, patent-protected prescription medicine in many markets, with limited low-cost generic supply in the same strength/formulation and distribution channels. Brand-name pricing also reflects the cost of maintaining sales and marketing networks, prescriber-facing materials, and ongoing regulatory/compliance work across regions.
In addition, rasagiline is typically prescribed for Parkinson’s disease and is often covered under specialty pharmacy or strict distribution arrangements in some countries, which can raise the final price patients see.
Is it expensive because it is still under patent, or because generics aren’t available?
If a country is still in the brand’s exclusivity window (patent or other market exclusivity), generics may not be authorized yet or may be delayed, keeping prices elevated. If generics exist, price can still stay high when:
- only a few generic versions are available,
- manufacturers price aggressively due to limited competition,
- or patients must use a specific dosage form/strength that doesn’t have many interchangeable options.
How much of the price comes from “specialty pharmacy” and insurance rules?
Even when the drug’s wholesale price is not the only driver, patient out-of-pocket cost can rise due to:
- specialty pharmacy dispensing and higher pharmacy processing fees,
- formulary placement (for example, non-preferred or higher tiers),
- higher coinsurance or deductible structures,
- prior authorization requirements that affect which product is used.
That means the same prescription can feel “expensive” even when insurance coverage differs across plans or countries.
Does the dose schedule or formulation make it harder to compete on price?
Rasagiline is generally used once daily for Parkinson’s disease, and the economics of manufacturing and packaging matter. If a market has relatively small demand, fewer manufacturers invest in making it, which can reduce competitive pressure and keep prices up.
What can patients do to lower the cost?
Common options include asking the prescriber/pharmacist whether:
- a generic rasagiline is available in your country,
- there’s a lower-cost therapeutic alternative on your formulary (your neurologist can help choose based on symptom control and side-effect profile),
- you can switch to a different strength or dosage form if clinically appropriate,
- manufacturer assistance programs or discount cards exist for your region.
If you share your country (and whether you’re paying cash or through insurance), the most likely reason—patent/exclusivity, generic availability, or coverage tier—can be pinpointed more accurately.